A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 64-69

  Ross, A E ^a   Feng, F Y ^b   Ghadessi, M ^c   Erho, N ^c   Crisan, A ^c   Buerki, C ^c   Sundi, D ^a   Mitra, A P ^d   Vergara, I A ^c   Thompson, D J S ^e   Triche, T J ^c,d   Davicioni, E ^c   Bergstralh, E J ^f   Jenkins, R B ^f   Karnes, R J ^f   Schaeffer, E M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GenomeDx Biosciences Inc   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e EMMES Canada   (Canada)

^f MAYO CLINIC   (United States)

Author keywords

biochemical recurrence; clinical validation; genomic classifier; metastasis; prognostic models

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; CANCER GRADING; DISEASE COURSE; GENETICS; GENOMICS; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; REPRODUCIBILITY;

AGED; DISEASE PROGRESSION; GENOMICS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84894032450     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.49     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. Cancer Stat 2012;62:10-29.
2. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-1123.
3. Moul J. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-1642.
4. Punnen S, Cooperberg MR, D'Amico A V, Karakiewicz PI, Moul JW, Scher HI et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013 (e-pub ahead of print).
5. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci M a, Partin AW et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32-39.
6. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181:1998-2006.
7. Patel AR, Stephenson AJ. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nature reviews. Urology 2011;8:385-392.
8. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Kevin M, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-2041.
9. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-2769.
10. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T et al. Early versus delayed hormonal therapy for prostate-specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004;171:1141-1147.
11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
12. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Yossepowitch O, Vickers AJ et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
13. Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagno 2010;12:409-417.
14. Thompson RH, Blute ML, Slezak JM, Bergstralh EJ, Leibovich BC. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? J Urol 2007;178:459-463.
15. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-1172.
16. Erho N, Crisan A, Vergara I a, Mitra AP, Ghadessi M, Buerki C et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013;8:e66855.
17. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-125.
18. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013. http://linkinghub.elsevier.com/retrieve/pii/S002253471304603X (e-pub ahead of print).
19. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039-5046.
20. Stephenson AJ, Scardino PT, Eastham JA, Bianco Jr FJ, Dotan A, Diblasio CJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2008;23:7005-7012.
21. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
22. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-344.
23. Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decision Making 2008;8:53.
24. Moul JW, Bañez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology 2007;21:1436-1445.
25. Lin DY, Ying Z. Cox regression with incomplete covariate measurements. J Am Statist Assoc 88:1341-1349.
26. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999;94:496-509.
28. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 2013;50:1064-1072.
29. Murphy RC, Kawashima A, Peller PJ. The utility of 11C-choline PET/CT for imaging prostate cancer: a pictorial guide. Am J Roentgenol 2011;196:1390-1398.
30. Ding Z, Wu C-J, Chu GC, Xiao Y, Ho D, Zhang J et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-273.
31. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.